It is time to protect patients with asthma from potential overexposure to oral corticosteroids (OCS) – and to recognize OCS overuse for what it often is: a treatment plan failure.

OCS carry serious health risks (page 2). Innovative treatment options target certain types of severe or difficult-to-control asthma in ways never-before possible, reducing the need for OCS. Today, OCS use has become a signal that a patient may need an updated treatment plan, or support with adherence concerns. While OCS can be an important tool in managing asthma in certain cases, use should always be carefully monitored by a qualified asthma specialist, or a primary care provider with asthma expertise. NOTE: OCS should not be confused with ICS (inhaled corticosteroids), which have fewer risks (page 2).

Within this context, we, the undersigned, are embarking upon a collaborative, systematic effort to curb OCS overexposure by:

1. Educating patients and their caregivers about (1) the risks associated with OCS; (2) the importance of adherence to other asthma medicines; and (3) advanced treatment options.
2. Ensuring that patients have access to qualified asthma specialists, or primary care providers with asthma expertise, who can (1) address adherence concerns; (2) determine if a patient has a severe, difficult-to-control form of asthma that might benefit from innovative targeted treatments; and (3) carefully monitor OCS use.
3. Supporting healthcare providers (allergists, pulmonologists, and primary care) to develop and adopt OCS-sparing strategies and practice shared decision-making.
4. Urging government agencies to modernize public health policies and materials to reflect the importance of OCS-sparing interventions.
5. Petitioning payers to adopt OCS-sparing strategies by providing appropriate and timely access to conventional and advanced

PATIENT INSIGHTS

A recent survey of 519 adults with asthma found that:

- Nearly 85% used at least one burst of OCS in the past 12 months.
- 64% had done so two or more times.
- About 20% did not equate >2 bursts of OCS (in a 12-month period) with poor asthma control or asthma severity.
- 78% of those who currently see an asthma specialist had received an OCS Rx from someone other than their specialist.
- 70% of those who currently see an asthma specialist report their doctor has talked to them about the risks/side effects associated with the overuse of OCS.
- Over half of patients surveyed were not aware of other innovative treatments options for severe or hard-to-control asthma.

* Polling conducted by the Asthma and Allergy Foundation of America, June 2018.
treatment options based on the clinical judgment of the treating HCP in consultation with the patient.

6. Ensuring primary and urgent / emergency care providers recognize when to refer patients to an asthma specialist, or a primary care provider with asthma expertise.

7. Empowering urgent / emergency care providers, pharmacists, asthma educators, and other health professionals to engage with patients about OCS risks at point-of-care.

ABOUT ASTHMA

Asthma is a chronic lung condition affecting 26.5 million Americans. Four to ten percent of the total asthma population are believed to have severe asthma. One study* revealed that U.S. patients using OCS short-term doubled their risk for fracture, tripled it for blood clots, and had a fivefold increased risk for sepsis.* Study was not solely focused on patients using OCS to manage asthma.

Other OCS Risks include:

Short-term:
- Elevated eye pressure (glaucoma)
- Fluid retention (causing swelling in lower legs)
- High blood pressure
- Problems with mood, memory, and behavior
- Weight gain (abdomen, face, and neck)

Longer-term:
- Cataracts (clouded vision)
- High blood sugar (can trigger or worsen diabetes)
- Infections
- Osteoporosis
- Thin skin, bruising, slower wound healing

INHALED VS. ORAL CORTICOSTEROIDS

Conventional medications often include inhaled corticosteroids, which are not the same as OCS and result in much lower overall steroid exposure than even one course of OCS.

The following organizations served as thought partners in the assembly of this statement: AstraZeneca, Boehringer Ingelheim, Boston Scientific, GlaxoSmithKline, Novartis, Sanofi & Regeneron.